Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim - LARVOL DELTA

Risankizumab vs Deucravacitinib in Adults With Moderate Plaque Psoriasis: Week 16 Subgroup Results From the IMMpactful Study (AAD 2026) - P4 | "Safety data were generally consistent with known profiles of both treatments. This analysis suggests that risankizumab provides greater clinical improvements vs deucravacitinib in patients with moderate plaque psoriasis across patient subgroups with safety outcomes consistent with the known safety profile of risankizumab."

Clinical • Dermatology • Immunology • Plaque Psoriasis • Psoriasis • TYK2

Specialty Pharmacy Interventions in Plaque Psoriasis and Psoriatic Arthritis: A 4-Year Institutional Review (AAD 2026) - "We identified n=911 with plaque psoriasis and/or psoriatic arthritis, with the five most prescribed systemics being: risankizumab-rzaa(RIS)=28.2%, apremilast(APR)=22.7%, secukinumab(SEC)=13.1%, ustekinumab(UST)=11.6%, ixekizumab(IXE)=11.3%. While RIS was the most prescribed medication, APR had the most interventions in each category, most notably interventions related to side-effects, drug-drug interactions, medication discontinuation, or adjunctive medications or healthcare visits required to address an issue. This study also highlights the benefits of an academic SP to improve patient care and medication management."

Clinical • Review • Dermatology • Immunology • Inflammatory Arthritis • Plaque Psoriasis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Quality of Life Improvements in Patients with Genital or Scalp Psoriasis Receiving Risankizumab: 16-Week Results from the UnIMMited Randomized Placebo-Controlled Trial (AAD 2026) - P4 | "Patients with genital or scalp psoriasis were more likely to report no impact of skin symptoms or embarrassment/self-consciousness on their lives after 16 weeks of treatment with risankizumab."

Clinical • HEOR • Dermatology • Immunology • Pruritus • Psoriasis

Long-Term Safety Assessment of Risankizumab in Psoriatic Disease: An Integrated Interval Analysis of Clinical Trial Data (AAD 2026) - "EAERs either decreased or stayed consistent over time and cumulative rates for malignancy remained within benchmarks, supporting the long-term safety of risankizumab for treating psoriatic disease."

Clinical • Immunology • Infectious Disease • Novel Coronavirus Disease

Superior Modulation of the IL-23–IL-17 Axis by Risankizumab Compared With Deucravacitinib at Week 16: Serum Biomarker Analysis From IMMpactful, a Phase 4, Randomized, Open-Label, Head-to-Head Study in Moderate Plaque Psoriasis (AAD 2026) - P4 | "The greater effects on disease-associated cytokines observed with risankizumab provide molecular evidence to support the observed clinical superiority over deucravacitinib. Further investigation, especially within psoriatic lesions, is warranted to better understand the molecular mechanisms involved."

Biomarker • Clinical • Head-to-Head • P4 data • Cardiovascular • Dermatology • Immunology • Inflammation • Plaque Psoriasis • Psoriasis • CRP • IL17A • IL17C • IL22 • IL23A • TYK2

Effects of interleukin-23 inhibitors on carotid intima-media thickness in patients with psoriasis (AAD 2026) - "Twelve patients were recruited (7 on risankizumab, 3 on guselkumab, and 2 on tildrakizumab), with a mean age of 53 ± 7.1 years, a mean PASI of 7 ± 5.2, a mean BMI of 29.9 ± 4, an average of 1.6 ± 1 prior biologic therapies, and a mean baseline cIMT of 0.78 ± 0.19 mm. These results suggest that IL-23 inhibitors may reduce cIMT and total cholesterol in patients with psoriasis, potentially lowering CVR. Larger studies with longer follow-up are required to validate these results."

Clinical • Cardiovascular • Dermatology • Immunology • Inflammation • Psoriasis • IL23A

Long-Term Efficacy of Risankizumab in Maintenance of Non-Radiographic Progression in Patients With Active Psoriatic Arthritis: 5-Year Data From the KEEPsAKE 1 Phase 3 Trial (AAD 2026) - "The proportion of RZB-treated patients without radiographic progression was high and consistent over 244 weeks, and the vast majority (≥90%) of those without progression at W52 maintained that outcome, indicating that RZB provides sustained and durable inhibition of structural damage in patients with PsA."

Clinical • P3 data • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Cutaneous Crohn’s Disease: A Systematic Review of Epidemiology, Clinical Manifestations, Diagnosis, and Treatment (AAD 2026) - "Ustekinumab was effective in anti-TNF–refractory disease, while risankizumab and upadacitinib showed complete clearance in isolated reports. Conventional agents (azathioprine, corticosteroids) offered only partial, often transient, benefit... CCD remains underrecognized and frequently misdiagnosed. Early biopsy and multidisciplinary evaluation are essential. While anti-TNF therapy remains standard, emerging IL-23 and JAK inhibitors represent promising options."

Clinical • Review • Crohn's disease • Dermatitis • Dermatopathology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Psoriasis • IL23A

Effect of Risankizumab Versus Deucravacitinib on Psoriasis-Related Symptoms and Quality of Life in Patients With Moderate Plaque Psoriasis: Results From the IMMpactful Trial at Week 16 (AAD 2026) - P4 | "Conclusions Patients with moderate plaque psoriasis treated with RZB achieved higher skin clearance than those treated with DEU. Higher skin clearance resulted in increased symptom relief and better QoL."

Clinical • HEOR • Dermatology • Immunology • Plaque Psoriasis • Psoriasis • TYK2

Risk of infections in patients with psoriasis treated with biologic agents and new oral small molecules. BIOBADADERM Registry. (AAD 2026) - " We analyzed crude incidence rates of overall, serious, recurrent, and infections of special interest in patients treated with etanercept, infliximab, certolizumab, adalimumab, ustekinumab, secukinumab, ixekizumab, brodalumab, bimekizumab, guselkumab, risankizumab, tildrakizumab, apremilast, and dimethyl fumarate. Modern systemic therapies for psoriasis show a favorable infection safety profile in real-world settings. IL-17 inhibitors appear to increase the risk of Candida infections, while some biologics may reduce the incidence of respiratory and viral infections."

Clinical • Candidiasis • Dermatology • Human Papillomavirus Infection • Immunology • Infectious Disease • Nephrology • Novel Coronavirus Disease • Psoriasis • Respiratory Diseases • IL17A

Beyond Trial-and-Error: Mechanism-Guided Use of Biologics in Scalp Psoriasis (AAD 2026) - "Ustekinumab offered modest scalp improvement but lacked dedicated trials. IL-17 inhibitors (secukinumab, ixekizumab, brodalumab, bimekizumab) consistently produced the most rapid clearance, with several maintaining high rates of complete response in long-term follow-up. IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab) provided excellent durability, with real-world evidence confirming sustained clearance. No scalp-specific outcomes were reported for certolizumab... Biologic selection in scalp psoriasis can move beyond trial-and-error toward mechanism-guided therapy. IL-17 inhibitors are best suited for rapid scalp clearance, while IL-23 inhibitors may optimize long-term durability. These findings support the development of a practical, scalp-specific treatment algorithm to address one of the most visible and burdensome manifestations of psoriasis."

Dermatology • Immunology • Psoriasis • CD8 • IL22 • IL23A

Comparative risk of psoriatic arthritis in psoriasis patients on immunomodulators (AAD 2026) - "The immunomodulatory agents assessed included Adalimumab, Infliximab, Ixekizumab, Secukinumab, Tildrakizumab, Certolizumab pegol, Risankizumab, Etanercept, Guselkumab, and Ustekinumab. Inhibition of this inflammation by immunomodulators could impede PsA progression. Physicians can consider Risankizumab, Guselkumab, and Ustekinumab as treatment options for PsO patients with PsA risk factors to mitigate disease progression and improve patients’ quality of life."

Clinical • Immunomodulating • Cardiovascular • Dermatology • Diabetes • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Gout • Hypertension • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Metabolic Disorders • Obesity • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL23A • JAK1 • JAK3 • TNFA

Beyond Monotherapy: Synergistic TYK2 and IL-23 Inhibition for the Effective Management of Treatment-Resistant Psoriasis (AAD 2026) - "Over several years, he failed multiple therapies including topical corticosteroids, oral prednisone, and systemic immunosuppressants (methotrexate, cyclosporine, mycophenolate). Biologic agents such as dupilumab, ixekizumab, and apremilast were also ineffective...Initial risankizumab monotherapy (IL-23 inhibitor) reduced BSA from 65% to 20%. Due to incomplete clearance, deucravacitinib (TYK2 inhibitor) was added, resulting in further improvement to 4% BSA over 16 months. The combination was well tolerated with no adverse effects. This case highlights the potential efficacy of dual IL-23 and TYK2 inhibition and supports individualized, flexible treatment strategies for refractory psoriasis."

Monotherapy • Atopic Dermatitis • Dermatology • Immunology • Pruritus • Psoriasis • IL17A • IL23A • IL4 • TYK2

Biologic treatment in Psoriasis and Hidradenitis Suppurativa patients with active malignancy: Experience from a Tertiary Care Hospital. (AAD 2026) - "Three patients were on adalimumab at cancer diagnosis; all switched to a different biologic class afterward. Biologic agents used included ustekinumab (n=1), tildrakizumab (n=4), guselkumab (n=1), and risankizumab (n=3)...This patient was not eligible for curative treatment, received palliative care, and died during follow-up. To sum up, biologic therapy may be feasible in selected patients with recent malignancy under close monitoring, preferring IL-23 inhibitors due to their safety profile."

Clinical • Colorectal Adenocarcinoma • Colorectal Cancer • Dermatology • Hidradenitis Suppurativa • Immunology • Lung Adenocarcinoma • Lung Cancer • Oncology • Palliative care • Prostate Adenocarcinoma • Prostate Cancer • Psoriasis • Solid Tumor • Squamous Cell Carcinoma • Supraglottic Laryngeal Cancer • IL23A

PRT09 Sailing into Clear Horizons (AAD 2026) - "Sponsored by: Abbvie DESCRIPTION A Review of SKYRIZI (risankizumab-rzaa) Clinical Efficacy and Safety Data"

Safety Outcomes of IL-23 Versus IL-17 Inhibitors in Psoriasis: A Multicenter Real-World Study (AAD 2026) - "Adults (≥18 years) with psoriasis initiating an IL-23 inhibitor (guselkumab, risankizumab, tildrakizumab) were compared to those commencing an IL-17 inhibitor (secukinumab, ixekizumab, brodalumab). This first multicenter, real-world head-to-head comparison of IL-23 and IL-17 inhibitors in psoriasis demonstrates a therapeutic trade-off: IL-23 agents reduce infection and mortality risks but increase malignancy and NMSC risks relative to IL-17 inhibitors. These findings offer pivotal evidence to inform individualized, long-term biologic selection in psoriasis, addressing a major gap in dermatologic care."

Clinical • Real-world • Real-world evidence • Dermatology • Genetic Disorders • Herpes Zoster • Immunology • Infectious Disease • Non-melanoma Skin Cancer • Pneumonia • Psoriasis • Respiratory Diseases • Septic Shock • Skin Cancer • Solid Tumor • Varicella Zoster • IL17A • IL23A

High treatment targets associated with quality of life improvement in psoriasis (AbbVie Press Release) - "A subgroup analysis of 16-week results from the IMMpactful trial evaluating treatment outcomes among biologic-naïve patients with moderate plaque psoriasis receiving risankizumab (RZB) compared with deucravacitinib (DEU) will be presented. Results demonstrated that patients with higher levels of skin clearance (PASI 90 [RZB 57.3% vs DEU 22.9%] and PASI 100 [RZB 27.5% vs DEU 6.5%]), had greater resolution of psoriasis symptoms and quality of life (Psoriasis Symptom Scale 0/1 [RZB 58.0% vs DEU 26.3%] and DLQI 0/1 [RZB 64.1% vs DEU 30.5%]). Findings from the 52-week data set will be presented at a future medical congress this year."

HEOR • P4 data • Plaque Psoriasis • Psoriasis

Psoriasis in Difficult-to-Treat Areas: A Multicentre, Real-World Retrospective Study Analyzing the Impact of Non-Invasive Imaging Techniques (Dermoscopy, Reflectance Confocal Microscopy and Optical Coherence Tomography) to Monitor the Effectiveness of Risankizumab in the Treatment of Plaque Psoriasis of the Legs. (PubMed, Clin Pract) - "Risankizumab induced rapid, significant regression of psoriatic changes, normalizing vascular patterns and skin architecture and reducing epidermal thickness. Findings support its efficacy and rapid onset of action in difficult-to-treat areas and highlight the value of non-invasive imaging for monitoring."

Journal • Real-world evidence • Retrospective data • Dermatology • Immunology • Oncology • Psoriasis

Quality of life improvement for patients with high impact areas of psoriasis (AbbVie Press Release) - "Genital and scalp psoriasis is associated with increased patient burden and impact on quality of life that can lead to anxiety, depression and social avoidance for some patients...Results from an analysis of quality of life improvements for patients treated with risankizumab at 16 weeks (assessed by DLQI) showed that 72% to 88.9% achieved individual DLQI 0/1 in Study-G and 83.3% to 100% achieved individual DLQI 0/1 in Study-S....the Food and Drug Administration (FDA) approved the supplemental biologics license application to update the U.S. Prescribing Information for risankizumab-rzaa (SKYRIZI) with key efficacy and safety results for genital and scalp psoriasis from Study-G and Study-S of the UnlIMMited program."

FDA approval • HEOR • P4 data • Psoriasis

Maintenance of radiographic nonprogression outcomes in psoriatic arthritis (AbbVie Press Release) - "An analysis reviewing the long-term (five-year) efficacy and radiographic outcomes of risankizumab from the KEEPsAKE-1 Phase 3 trial showed 88% of patients had no radiographic progression (as defined by change in modified Total Sharp Score < 0) through week 244."

P3 data • Psoriatic Arthritis

Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=213 | Active, not recruiting | Sponsor: Chong Kun Dang Pharmaceutical | Recruiting ➔ Active, not recruiting

Enrollment closed • First-in-human • Crohn's disease • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Ulcerative Colitis

IGA NEPHROPATHY FOLLOWING RISANKIZUMAB THERAPY FOR PSORIATIC ARTHRITIS: A CASE REPORT (ISN-WCN 2026) - "He was diagnosed with psoriatic arthritis in 2018 and treated sequentially with brodalumab, adalimumab, and ixekizumab, but these agents failed to adequately control his symptoms. While IgAN has been reported in association with the IL-12/23p40 inhibitor ustekinumab, no previous case of risankizumab-associated IgAN has been described. Further accumulation of biologic-associated IgAN cases, including those involving IL-23p19 inhibition, may help elucidate the underlying disease mechanisms."

Case report • Clinical • Crohn's disease • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Glomerulonephritis • IgA Nephropathy • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Psoriasis • Psoriatic Arthritis • Renal Disease • Rheumatology • Seronegative Spondyloarthropathies • Ulcerative Colitis • IL12A • IL23A • IL4

Outcomes of Risankizumab in Patients with Crohn's Disease and Prior Ustekinumab Exposure in a Multicenter Academic Institution. (PubMed, Dig Dis Sci) - "RZB appears to be an effective treatment option for patients with CD and prior UST use, particularly those with secondary loss of response. A higher number of previously trialed therapies was associated with reduced likelihood of response, underscoring the importance of early, strategic treatment sequencing."

Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • CRP

Rapid desensitization to intravenous risankizumab after anaphylaxis in a patient with Crohn's disease: a case report (EAACI 2026) - No abstract available

Case report • Clinical • Crohn's disease • Immunology • Inflammatory Bowel Disease

Development of Celiac Disease After Immunotherapy: A Case Series. (PubMed, Gastro Hep Adv) - "Celiac disease developed in 3 patients after initiating biologic therapy: a 21-year-old female with psoriasis receiving ixekizumab (interleukin-17 antagonist) and risankizumab (interleukin-23 antagonist); a 49-year-old female with invasive ductal carcinoma of the breast after pertuzumab (human epidermal growth factor receptor 2 antagonist); and an 82-year-old male taking cabozantinib (multityrosine kinase inhibitor) for renal cell carcinoma. We have identified 3 cases of celiac disease that presented after initiating new immune-modulating medications. It is important to consider celiac disease and nonceliac villous atrophy in the differential for diarrhea developing during or after a new therapy as it heavily impacts management and may eliminate the need for alternate therapies that include steroid courses, cessation of therapy, or even gluten-free diet."

Journal • Breast Cancer • Celiac Disease • Dermatology • Genito-urinary Cancer • Immunology • Oncology • Psoriasis • Renal Cell Carcinoma • Solid Tumor • HER-2